Titre :

Évaluation des interactions médicamenteuses chez des patients traités pour un cancer pulmonaire ou digestif

Titre traduit :

Evaluation of drug interactions in patients treated for a lung or digestive cancer

Auteur(s) :

Ghysel, Vincent [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Tresch, Emmanuelle [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Marliot, Guillaume [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Nicot, Romain [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Advanced Drug Delivery Systems (ADDS) - U1008
Lambert, Marc [Auteur]
Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Carbonnelle, Guillaume [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Lartigau, Eric [Auteur]
Centre de Recherche en Informatique, Signal et Automatique de Lille (CRIStAL) - UMR 9189
Lefebvre, Gautier [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]

Titre de la revue :

Bulletin du Cancer

Nom court de la revue :

Bull Cancer

Numéro :

107

Pagination :

1108-1117

Date de publication :

2020-10-01

ISSN :

1769-6917

Mot(s)-clé(s) :

interaction médicamenteuse
toxicité
polymédication
chimiothérapie anti- cancéreuse

Mot(s)-clé(s) en anglais :

Anticancer chemotherapy
Polypharmacy
Toxicity
Drug interaction

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: Cancer patients are particularly at risk for drug interactions. However, in oncology, this risk has not been studied in depth in France. The main objective of this study was to describe the proportion of drug ...
Lire la suite >BACKGROUND: Cancer patients are particularly at risk for drug interactions. However, in oncology, this risk has not been studied in depth in France. The main objective of this study was to describe the proportion of drug interactions in patients with lung or digestive cancer. METHODS: The drug prescriptions of 93 patients were analyzed from may 27th, 2019 to July 07th, 2019 using two software programs (Thériaque™ and DDI Predictor™) in oncology patients hospitalized in our comprehensive cancer center. RESULTS: Of the 88 patients included in the study, 544 drug interactions were identified, in 66 patients (75.0%, 95% CI: 64.6-83.6). For 20/88 patients (22.7% CI: 14.5-32.9) a non-recommended combination or a theoretical contraindication was reported. Etoposide was the anticancer molecule most involved in combinations that are contraindicated or not recommended. No combinations defined as not recommended or contraindicated were observed in any of the 49 patients treated with chemotherapy during their hospitalization. The most common toxicities were alertness and metabolic disorders, including hyperkalemia. The use of three or more drugs was a risk factor for drug interactions (83 vs. 23%, P<0.001). CONCLUSIONS: Drug interactions remain a major concern in cancer hospitalized patients. It is important to continue and strengthen the collaboration between physicians and pharmacists in order to better prevent their occurrence.Lire moins >

Langue :

Anglais
Français

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
CNRS
Centrale Lille
Inserm
Institut Pasteur de Lille
Université de Lille

Collections :

• Advanced Drug Delivery Systems (ADDS) - U1008
• Centre de Recherche en Informatique, Signal et Automatique de Lille (CRIStAL) - UMR 9189
• Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167

Date de dépôt :

2021-01-20T15:59:24Z
2024-02-16T09:58:52Z